The Stanford Detour That Wasn't a Detour
At Stanford, Siddiqui did not coast. She worked in Anshul Kundaje's lab, applying deep learning to genomics - the exact intersection that would later power Orchid's analysis engine. She also worked with Sebastian Thrun, the robotics and self-driving pioneer who had turned his attention to medical imaging. Then she taught her own course on reproductive technology, which functioned less as a class and more as a research sprint with students, mapping what genomic tools existed and what was still missing.
The missing piece was obvious: nobody was sequencing the whole embryo genome. Tests existed, but they were narrow. They looked at fragments. Siddiqui looked at what entire-genome sequencing could do in a research context and saw that the barrier to clinical translation was not scientific. It was logistical, financial, and organizational. Someone had to build the company.
"Parents already choose their kid with IVF. Orchid isn't any different."
- Noor SiddiquiShe was 26 when she founded Orchid. The company's thesis was bold enough to attract serious critics - geneticists who questioned the clinical utility of polygenic risk scores in embryo selection, ethicists who raised concerns about selection pressure, regulators who wanted to understand the validation data. Siddiqui engaged with all of them. Not to avoid controversy. Because she believed the science held up.
The 2023 Series A was led by Prometheus Fund, with participation from Conviction Capital, Elad Gil, and a constellation of operators and founders who understood what they were backing. Anne Wojcicki, who built 23andMe's consumer genetics empire, wrote a check. Brian Armstrong, who built Coinbase, wrote a check. Fidji Simo and Dylan Field joined too. This was not a bet on a lab curiosity. This was a bet that Orchid's clinical-grade, whole-genome embryo test would become standard-of-care in IVF within a decade.
"Most kids are born by accident. And yet we stigmatize parents who plan ahead? Who screen embryos to prevent deadly, (now) preventable diseases?"
- Noor Siddiqui, on XThe cost is real: $2,500 per embryo, approximately $12,500 for a cycle with five biopsied embryos. Siddiqui does not minimize this. She talks about cost reduction as a prerequisite for the mission, not a footnote. The technology curve in sequencing is predictable. Orchid's job is to get the clinical infrastructure right before prices fall, so it's ready to scale when they do.
Each test includes genetic counselor support before and after. The report covers chromosomal abnormalities, monogenic disease risk, polygenic scores for complex conditions, and de novo mutation detection. Orchid's lab is CAP and CLIA certified. Results come back in roughly three weeks.
Siddiqui's argument is not subtle: if we can prevent a child from inheriting the mutation that took her mother's vision, and we choose not to because of stigma or inertia, that is a failure. Not of technology. Of will.
The Podcast and the Platform
Beyond the company, Siddiqui runs "Conceivable with Noor" - a podcast on Apple Podcasts, Spotify, and Amazon Music that covers reproductive technology, genetic science, and the future of fertility. She is not shy about discussing what she calls fertility collapse as a threat to civilization. She interviews scientists, physicians, and ethicists. She is building a public intellectual platform around the intersection of genomics and reproduction, and she is doing it under her own name.
On X (@noor_siddiqui_), she has over 14,000 followers and posts regularly on genetics, reproductive policy, and the science behind Orchid's tests. She does not write corporate PR. She writes like someone with opinions, which is to say: she writes like a founder.